1. Show article details.

    BRIEF-NovaBay Pharmaceuticals Files For Offering Of Up To $5.6 Mln Of Shares Of Common Stock

    Reuters – 8:32 AM ET 06/15/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $5.6 MILLION OF SHARES OF COMMON STOCK - SEC FILING Source: Further company coverage:

  2. Show article details.

    BRIEF-NovaBay Says It Files Prospectus Related To Resale Of 10.2 Million Shares Held By Stockholders

    Reuters – 5:56 PM ET 05/15/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS SAYS IT FILES PROSPECTUS RELATED TO RESALE OF 10.2 MILLION SHARES HELD BY STOCKHOLDERS - SEC FILING Source text: Further company coverage:

  3. Show article details.

    BRIEF-NovaBay Pharmaceuticals Says Entered Second Amendment To Certain Promissory Note

    Reuters – 5:04 PM ET 05/15/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS (NBY)- ON MAY 14, CO ENTERED INTO SECOND AMENDMENT TO THAT CERTAIN PROMISSORY NOTE, DATED FEB 27, 2019 PAYABLE TO PIONEER PHARMA. * NOVABAY PHARMACEUTICALS (NBY)- INTEREST PAYMENT WAS AMENDED FROM PAYMENT OF $300,000 TO DELIVERY OF 65,178 UNITS OF NEUTROPHASE TO PIONEER PHARMA.

  4. Show article details.

    NovaBay Pharmaceuticals Issues Letter to Stockholders

    Business Wire – 6:50 AM ET 05/14/2020

    NovaBay® Pharmaceuticals, Inc. announces that CEO Justin Hall has issued the following letter to stockholders: To My Fellow Stockholders: As pandemic-related shelter-in-place restrictions are beginning to lift in certain geographies and Americans are preparing to return to school, work and social activities, NovaBay has focused on offering our fellow Americans products they need to help them st...

  5. Show article details.

    BRIEF-Novabay Pharmaceuticals Reports First Quarter 2020 Financial Results

    Reuters – 5:53 PM ET 05/07/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS. * Q1 LOSS PER SHARE $0.06. * EMERGENCY USE APPROVAL FOR COVID-19 TEST KITS FILED ON APRIL 17, 2020. * QTRLY NET PRODUCT REVENUE OF $1.9 MILLION, UP 30% YEAR-OVER-YEAR. * ARE NEARING MILESTONE OF SELLING ONE MILLION KN95 MASKS.

  6. Show article details.

    BRIEF-Novabay Pharmaceuticals Appoints Andrew Jones As CFO

    Reuters – 7:39 AM ET 05/05/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS APPOINTS ANDREW D. JONES CHIEF FINANCIAL OFFICER. * NovaBay Pharmaceuticals Inc (NBY) - ANNOUNCES APPOINTMENT OF ANDREW D. JONES AS CHIEF FINANCIAL OFFICER AND TREASURER, EFFECTIVE MAY 1, 2020 Source text for Eikon: Further company coverage:

  7. Show article details.

    CORRECTING and REPLACING NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer

    Business Wire – 6:50 AM ET 05/05/2020

    Please replace the release with the following revised version, which includes a change in the effective date in the first paragraph, first sentence to May 4, 2020.

  8. Show article details.

    BRIEF-Novabay Pharmaceuticals - May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $4.3 Mln

    Reuters – 6:06 PM ET 04/27/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS (NBY) - MAY OFFER, SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $4.3 MILLION FROM TIME TO TIME THROUGH LADENBURG Source text Further company coverage:

  9. Show article details.

    BRIEF-Novabay Pharmaceuticals Signs Agreement To Distribute COVID-19 Antibody Rapid Point-Of-Care Test To U.S. Healthcare Professionals

    Reuters – 7:07 AM ET 04/20/2020

    NovaBay Pharmaceuticals Inc (NBY): * NOVABAY PHARMACEUTICALS SIGNS AGREEMENT TO DISTRIBUTE COVID-19 ANTIBODY RAPID POINT-OF-CARE TEST TO U.S. HEALTHCARE PROFESSIONALS. * NOVABAY PHARMACEUTICALS (NBY) - TO SUBMIT ISO 13485 AND CE MARK CERTIFIED FLUORECARE TEST KIT UNDER FDA'S EAU AND 510 CLEARANCE FOR U.S. COMMERCIAL USE Source text for Eikon: Further company coverage:

  10. Show article details.

    NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to U.S. Healthcare Professionals

    Business Wire – 6:50 AM ET 04/20/2020

    Company to submit the ISO 13485 and CE Mark certified fluorecare® test kit under FDA’s EAU and 510 clearance for U.S. commercial use NovaBay® Pharmaceuticals, Inc. announces an agreement with Shenzhen Microprofit Biotech Co., Ltd. to become the exclusive U.S. distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19.

Page:

Today's and Upcoming Events

  • Aug
    05

    NBY to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    NBY announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.